Perioperative management of P2Y12 inhibitors in patients undergoing cardiac surgery within 1 year of PCI.
Davide CaoJulie A SwainSamantha SartoriMatteo NardinZhongjie ZhangAnastasios RoumeliotisJohny NicolasMauro ChiaritoRishi ChandiramaniCarlo A PivatoAlessandro SpiritoGennaro GiustinoGiulio G StefaniniGeorge D DangasUsman BaberDeepak L BhattDavid H AdamsSamin K SharmaAnnapoorna S KiniRoxana MehranPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Among patients undergoing cardiac surgery in the year after PCI, the perioperative risk of ischaemic and bleeding events might be influenced by P2Y12 inhibitor therapy in addition to other risk parameters, including the timing and urgency of the procedure.
Keyphrases
- cardiac surgery
- patients undergoing
- acute kidney injury
- percutaneous coronary intervention
- atrial fibrillation
- coronary artery disease
- acute myocardial infarction
- acute coronary syndrome
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- minimally invasive
- coronary artery bypass grafting
- heart failure
- bone marrow
- replacement therapy